Triple Negative Breast Cancer: Integrative Oncology Updates & Successful Strategies with Michael Traub, ND, FABNO, DHANP & Miranda LaBant, ND, MS
Breast cancer is the most common malignancy in women. Triple negative breast cancer (TNBC) is regarded as a more aggressive subtype with poorer prognosis and limited targeted therapies. TNBC is represented by the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER 2) and accounts for about 12.5-15% of all breast cancers.{1} TNBC is more frequent in younger age (<50 years), African American and Latina populations.{2} Germline mutations in the BRCA1 gene have been associated with TNBC. Approximately 70% of breast cancers arising in BRCA1 mutation carriers and up to 23% of breast cancers in BRCA2 carriers display a triple negative phenotype.{3} The key to innovative therapeutic options relies on the understanding of predictive biomarkers and molecular diversity of this cancer.
With the current lack of effective targeted therapies for TNBC, treatment regimens often fail to slow tumor progression. The goal of our presentation will be to provide an update on TNBC, including its clinicopathologic features, biomarkers and their prognostic and therapeutic potential as well as to highlight effective and successful integrative treatment strategies through case-based discussion.
Learning Objectives
Overview of TNBC statistics, prevalence, risk factors, incidence & mortality, recurrence rates
Review of presenting symptoms, screening test, biomarkers, CTC’s, diagnosis
Review of current conventional therapy guidelines for TNBC
Review of integrative therapeutics for TNBC
Highlighting strategies in successful case reports (3 cases)
Breast cancer is the most common malignancy in women. Triple negative breast cancer (TNBC) is regarded as a more aggressive subtype with poorer prognosis and limited targeted therapies. TNBC is represented by the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER 2) and accounts for about 12.5-15% of all breast cancers.{1} TNBC is more frequent in younger age (<50 years), African American and Latina populations.{2} Germline mutations in the BRCA1 gene have been associated with TNBC. Approximately 70% of breast cancers arising in BRCA1 mutation carriers and up to 23% of breast cancers in BRCA2 carriers display a triple negative phenotype.{3} The key to innovative therapeutic options relies on the understanding of predictive biomarkers and molecular diversity of this cancer.
With the current lack of effective targeted therapies for TNBC, treatment regimens often fail to slow tumor progression. The goal of our presentation will be to provide an update on TNBC, including its clinicopathologic features, biomarkers and their prognostic and therapeutic potential as well as to highlight effective and successful integrative treatment strategies through case-based discussion.
Learning Objectives
Overview of TNBC statistics, prevalence, risk factors, incidence & mortality, recurrence rates
Review of presenting symptoms, screening test, biomarkers, CTC’s, diagnosis
Review of current conventional therapy guidelines for TNBC
Review of integrative therapeutics for TNBC
Highlighting strategies in successful case reports (3 cases)
Breast cancer is the most common malignancy in women. Triple negative breast cancer (TNBC) is regarded as a more aggressive subtype with poorer prognosis and limited targeted therapies. TNBC is represented by the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER 2) and accounts for about 12.5-15% of all breast cancers.{1} TNBC is more frequent in younger age (<50 years), African American and Latina populations.{2} Germline mutations in the BRCA1 gene have been associated with TNBC. Approximately 70% of breast cancers arising in BRCA1 mutation carriers and up to 23% of breast cancers in BRCA2 carriers display a triple negative phenotype.{3} The key to innovative therapeutic options relies on the understanding of predictive biomarkers and molecular diversity of this cancer.
With the current lack of effective targeted therapies for TNBC, treatment regimens often fail to slow tumor progression. The goal of our presentation will be to provide an update on TNBC, including its clinicopathologic features, biomarkers and their prognostic and therapeutic potential as well as to highlight effective and successful integrative treatment strategies through case-based discussion.
Learning Objectives
Overview of TNBC statistics, prevalence, risk factors, incidence & mortality, recurrence rates
Review of presenting symptoms, screening test, biomarkers, CTC’s, diagnosis
Review of current conventional therapy guidelines for TNBC
Review of integrative therapeutics for TNBC
Highlighting strategies in successful case reports (3 cases)